Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186847 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
A Phase 2 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT02186847 is a Phase 2 study that has completed, run by NRG Oncology. The registered enrollment target is 170 participants.
The verdict
NCT02186847, a Phase 2 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Metformin hydrochloride may shrink tumors and keep them from coming back. It is not yet known whether chemotherapy and radiation therapy is more effective when given with or without metformin hydrochloride in treating stage III non-small cell lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Radiation Therapy
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2014-08 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02186847
The ClinicalTrials.gov registry entry for NCT02186847 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02186847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02186847 about?
NCT02186847 is a clinical study titled "Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer". This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the gr...
What is the current status of trial NCT02186847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2014-08. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT02186847?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiation Therapy (RADIATION), Metformin (DRUG).
Who is sponsoring clinical trial NCT02186847?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.